Loading…
No business profile yet.
Size ADARx Pharmaceuticals (ADRX) is a United States Industrials company (Biotechnology) with a market value of $1.47B, the 2004th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.23 on 6 Nov 2026.
Growth The operating margin is -2,562.1% (peer median 6.7%).
Valuation It trades at 407.0× enterprise value to sales against a peer median of 1.4× (most expensive of 19).
Capital Return on invested capital runs 165.6 points below its cost of capital (6.4% WACC).
Short interest Short interest is 1.7% of the free float (15 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $3.45M | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | $1.12M | -$1.50M |
| EBITDA | n/a | -$86.0M | -$56.7M |
| Net income | n/a | -$73.1M | -$46.4M |
| Free cash flow | n/a | $259M | -$49.0M |
| Capital expenditure | n/a | $2.94M | $455,000 |
| Total debt | $6.90M | $7.74M | $4.33M |
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ADRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.1% | -11.2% | 5th lowest of 21 |
| Distance from 52-week high | -43.0% | -39.0% | 8th lowest of 21 |
| Operating margin | -2,562.1% | 6.7% | lowest of 19 |
| EV / Sales | 407.0× | 1.4× | most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | -16.2% | 9.2% | least demanding of 15 |
| ROIC minus cost of capital | -165.6 pp | -2.8 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals ADRX | United States | $1.47B | n/a | n/a | -2,562% | 407.0× | -16.2% | n/a |
| MillerKnoll MLKN | United States | $1.48B | +32% | +1% | 6% | 0.8× | 7.3% | +9.3% |
| Hub HUBG | United States | $1.48B | -44% | n/a | n/a | n/a | n/a | n/a |
| Clarivate CLVT | United States | $1.50B | -16% | -9% | 8% | 2.4× | 13.4% | +14.4% |
| ICF International ICFI | United States | $1.43B | +14% | -8% | 8% | 1.0× | -2.2% | +4.4% |
| Global Ship Lease GSL | United States | $1.41B | -8% | +6% | 48% | 2.0× | -15.2% | +22.1% |
| Costamare CMRE | United States | $1.54B | -28% | -42% | 44% | 3.4× | -6.9% | +13.0% |
| Cadre CDRE | United States | $1.40B | +9% | +20% | 11% | 2.5× | 16.9% | +8.6% |
| ADI Global Distribution ADIG | United States | $1.39B | n/a | +14% | 4% | 0.4× | n/a | n/a |
| Cimpress CMPR | United States | $1.39B | -38% | +10% | 6% | 0.8× | 5.4% | +7.7% |
| JetBlue Airways JBLU | United States | $1.38B | -28% | +10% | -6% | 0.9× | n/a | n/a |
| Allient ALNT | United States | $1.38B | +22% | +11% | 9% | 2.7× | 27.9% | +8.6% |
| ERock EROC | United States | $1.56B | n/a | +43% | -19% | 6.4× | 12.5% | +42.5% |
| Helios Technologies HLIO | United States | $1.56B | -30% | +14% | 13% | 2.1× | 11.2% | +9.9% |
| Hillman Solutions HLMN | United States | $1.62B | +6% | +6% | 6% | 1.6× | 17.9% | +2.6% |
| Werner Enterprises WERN | United States | $1.62B | -26% | +15% | 2% | 0.8× | n/a | n/a |
| Distribution Solutions DSGR | United States | $1.62B | +27% | +6% | 4% | 1.2× | 15.5% | +41.3% |
| Accelevation ACCV | United States | $1.33B | n/a | n/a | n/a | n/a | n/a | n/a |
| Alamo ALG | United States | $1.63B | -18% | +2% | 7% | 1.0× | 7.0% | +6.6% |
| Healthcare Services HCSG | United States | $1.64B | +5% | +4% | 6% | 0.8× | 3.4% | +0.9% |
| AEVEX AVEX | United States | $1.29B | -59% | +143% | 11% | 3.4× | n/a | n/a |